Putting TDM knowledge into practice

Affiliations

Alan C Moss. Frontline Gastroenterol. 2019 Oct.

. 2019 Oct;10(4):327.

doi: 10.1136/flgastro-2018-101159. Epub 2019 Feb 1.

¹ Department of Gastroenterology, BIDMC/Harvard Medical School, Boston, Massachusetts, USA.

No abstract available

Keywords: IBD clinical; infliximab; therapeutic drug monitoring.

Conflict of interest statement

Competing interests: None declared.

1. Moore C, Corbett G, Moss AC. Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease. J Crohns Colitis 2016;10:619–25. 10.1093/ecco-jcc/jjw007 - DOI - PMC - PubMed
1. Vande Casteele N, Ferrante M, Van Assche G, et al. . Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320–9. 10.1053/j.gastro.2015.02.031 - DOI - PubMed
1. Feuerstein JD, Nguyen GC, Kupfer SS, et al. . American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology 2017;153:827–34. 10.1053/j.gastro.2017.07.032 - DOI - PubMed
1. Kamperidis V. The impact of therapeutic drug level monitoring on outcomes of patients with Crohn’s disease treated with Infliximab: real world data from a retrospective single centre cohort study. Frontline Gastroenterology 2019;10:330–6. - PMC - PubMed
1. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, et al. . Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 2014;20:1996–2003. 10.1097/MIB.0000000000000156 - DOI - PMC - PubMed